Dry Powder PA-824 Aerosols for Treatment of Tuberculosis in Guinea Pigs
- 1 April 2010
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 54 (4) , 1436-1442
Abstract
Novel treatments for multidrug-resistant tuberculosis (MDR-TB), extensively drug-resistant tuberculosis (XDR-TB), or latent TB are needed urgently. Recently, we reported the formulation and characterization of the nitroimidazo-oxazine PA-824 for efficient aerosol delivery as dry powder porous particles and the subsequent disposition in guinea pigs after pulmonary administration. The objective of the present study was to evaluate the effects of these PA-824 therapeutic aerosols on the extent of TB infection in the low-inoculum aerosol infection guinea pig model. Four weeks after infection by the pulmonary route, animals received daily treatment for 4 weeks of either a high or a low dose of PA-824 dry powder aerosol. Animals received PA-824 cyclodextrin/lecithin suspensions orally as positive controls, and those receiving placebo particles or no treatment were negative controls. The lungs and spleens of animals receiving the high dose of inhaled PA-824 particles exhibited a lower degree of inflammation (indicated by wet tissue weights), bacterial burden, and tissue damage (indicated by histopathology) than those of untreated or placebo animals. Treatment with oral PA-824 cyclodextrin/lecithin suspension resulted in a more significant reduction in the bacterial burden of lungs and spleen, consistent with a dose that was larger than inhaled doses (eight times the inhaled low dose and four times the inhaled high dose). However, histopathological analysis revealed that the extent of tissue damage was comparable in groups receiving the oral or either inhaled dose. The present studies indicate the potential use of PA-824 dry powder aerosols in the treatment of TB.Keywords
This publication has 24 references indexed in Scilit:
- Assessment of the Effects of the Nitroimidazo-Oxazine PA-824 on Renal Function in Healthy SubjectsAntimicrobial Agents and Chemotherapy, 2009
- Safety, Tolerability, and Pharmacokinetics of PA-824 in Healthy SubjectsAntimicrobial Agents and Chemotherapy, 2009
- Dry Powder Nitroimidazopyran Antibiotic PA-824 Aerosol for InhalationAntimicrobial Agents and Chemotherapy, 2009
- Powerful Bactericidal and Sterilizing Activity of a Regimen Containing PA-824, Moxifloxacin, and Pyrazinamide in a Murine Model of TuberculosisAntimicrobial Agents and Chemotherapy, 2008
- Drugs versus bugs: in pursuit of the persistent predator Mycobacterium tuberculosisNature Reviews Microbiology, 2008
- Inhaled Large Porous Particles of Capreomycin for Treatment of Tuberculosis in a Guinea Pig ModelAntimicrobial Agents and Chemotherapy, 2007
- New Tuberculosis Therapeutics: A Growing PipelineThe Journal of Infectious Diseases, 2007
- Combination Chemotherapy with the Nitroimidazopyran PA-824 and First-Line Drugs in a Murine Model of TuberculosisAntimicrobial Agents and Chemotherapy, 2006
- Adjunctive Salvage Therapy with Inhaled Aminoglycosides for Patients with Persistent Smear-Positive Pulmonary TuberculosisClinical Infectious Diseases, 2001
- Long-Term Retention and Clearance of Particles Inhaled by Mammalian SpeciesCritical Reviews in Toxicology, 1989